Penumbra, Inc. (PEN)

Market Cap	11.23B
Revenue (ttm)	1.19B
Net Income (ttm)	14.01M
Shares Out	38.52M
EPS (ttm)	0.36
PE Ratio	810.22
Forward PE	79.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	635,327
Open	303.00
Previous Close	303.12
Day's Range	290.55 - 304.11
52-Week Range	148.00 - 310.00
Beta	0.54
Analysts	Buy
Price Target	287.07 (-1.58%)
Earnings Date	Feb 18, 2025

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, S...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,500
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Financial Performance

In 2024, Penumbra's revenue was $1.19 billion, an increase of 12.86% compared to the previous year's $1.06 billion. Earnings were $14.01 million, a decrease of -84.59%.

Analyst Forecast

According to 16 analysts, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $287.07, which is a decrease of -1.58% from the latest price.

Price Target

$287.07

(-1.58% downside)

Analyst Consensus: Buy